Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
This review aims to comprehensively evaluate the published randomized clinical trials (RCTs) of vitamin D supplements as add-on therapy for MS patients.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Systematic review.
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Role of vitamin D as adjuvant therapy on multiple sclerosis: an updated systematic review and meta-analysis of randomized controlled trials
Source: Article title.
Role of vitamin D as adjuvant therapy on multiple sclerosis: an updated systematic review and meta-analysis of randomized controlled trials
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Role of vitamin D as adjuvant therapy on multiple sclerosis: an updated systematic review and meta-analysis of randomized controlled trials
Systematic review · European Journal of Medical Research · 2025
Original publication title
Role of vitamin D as adjuvant therapy on multiple sclerosis: an updated systematic review and meta-analysis of randomized controlled trials
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Multiple sclerosis (MS) is the most common demyelinating disorder affecting the central nervous system, with multiple risk factors suggested to be involved in the pathogenesis. Many studies have linked vitamin D deficiency to an increased risk of MS. This review aims to comprehensively evaluate the published randomized clinical trials (RCTs) of vitamin D supplements as add-on therapy for MS patients.
Source: BackgroundAbstract: What methods does the paper describe?
We systematically searched the Web of Science, Scopus, PubMed, and Cochrane databases up to August 2024 for the published RCTs evaluating the use of vitamin D for MS in adults. All included studies were screened and abstracted independently by two authors. Radiological and clinical outcomes were extracted, and the meta-analysis was conducted using Review Manager 5.4.
Source: MethodsAbstract: Results
Our meta-analysis, which included 21 studies with 1,903 patients (20.1% males), found that vitamin D supplementation significantly reduced expanded disability status scale scores (MD = − 0.17, p = 0.03), relapse rates (OR = 0.66, p = 0.02), and new T2 lesion formation (MD = − 0.48, p = 0.03) in patients with MS compared to controls, with minimal to no heterogeneity. However, there was no effect on the annual relapse rate (p = 0.81), timed 25-foot walk (p = 0.54), fatigue severity, or quality of life.
Subgroup analysis indicated a relapse rate reduction only in those treated for more than 12 months (OR = 0.53, p = 0.003), suggesting duration-dependent benefits of vitamin D.
Source: ResultsAbstract: Conclusions
Vitamin D supplementation produces statistically significant: yet clinically modest: reductions in disability progression, relapses, and new T2-lesion formation without demonstrable effects on fatigue or quality of life. Accordingly, it should be considered a potentially helpful adjunct pending more definitive evidence. Larger, dose-stratified trials powered for clinically meaningful endpoints are still needed before vitamin D can be endorsed as an efficacy-proven disease-modifying therapy.
Source: ConclusionsAuthors’ abstract
Background
Multiple sclerosis (MS) is the most common demyelinating disorder affecting the central nervous system, with multiple risk factors suggested to be involved in the pathogenesis. Many studies have linked vitamin D deficiency to an increased risk of MS. This review aims to comprehensively evaluate the published randomized clinical trials (RCTs) of vitamin D supplements as add-on therapy for MS patients.
Methods
We systematically searched the Web of Science, Scopus, PubMed, and Cochrane databases up to August 2024 for the published RCTs evaluating the use of vitamin D for MS in adults. All included studies were screened and abstracted independently by two authors. Radiological and clinical outcomes were extracted, and the meta-analysis was conducted using Review Manager 5.4.
Results
Our meta-analysis, which included 21 studies with 1,903 patients (20.1% males), found that vitamin D supplementation significantly reduced expanded disability status scale scores (MD = − 0.17, p = 0.03), relapse rates (OR = 0.66, p = 0.02), and new T2 lesion formation (MD = − 0.48, p = 0.03) in patients with MS compared to controls, with minimal to no heterogeneity. However, there was no effect on the annual relapse rate (p = 0.81), timed 25-foot walk (p = 0.54), fatigue severity, or quality of life.
Subgroup analysis indicated a relapse rate reduction only in those treated for more than 12 months (OR = 0.53, p = 0.003), suggesting duration-dependent benefits of vitamin D.
Conclusions
Vitamin D supplementation produces statistically significant: yet clinically modest: reductions in disability progression, relapses, and new T2-lesion formation without demonstrable effects on fatigue or quality of life. Accordingly, it should be considered a potentially helpful adjunct pending more definitive evidence. Larger, dose-stratified trials powered for clinically meaningful endpoints are still needed before vitamin D can be endorsed as an efficacy-proven disease-modifying therapy.
Publication and source details
Original title: Role of vitamin D as adjuvant therapy on multiple sclerosis: an updated systematic review and meta-analysis of randomized controlled trials
Ibrahim Serag; Mohamed Abouzid; Khalid Radwan Alsaadany; Mohamed Hendawy; Hossam Tharwat Ali; Yazan Yaseen; Mostafa Hossam El din Moawad
European Journal of Medical Research · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Mansoura UniversityOpen access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:18:18.699915+00:00
DOI: 10.1186/s40001-025-02981-x · PMC12341198